Yue Fei

National Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Key Laboratory Of Cancer Prevention And Therapy
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.

Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.

Journal: Leukemia
Published: December 17, 2025

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics.

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics.

Journal: American journal of hematology
Published: October 15, 2025

BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma.

BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma.

Journal: Cancer letters
Published: May 05, 2025

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study.

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study.

Journal: NPJ precision oncology
Published: September 18, 2024

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.

Journal: Blood
Published: September 12, 2024

A retrospective analysis of mature T- and NK-cell lymphomas.

A retrospective analysis of mature T- and NK-cell lymphomas.

Journal: Cancer biology & medicine
Published: March 28, 2024

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.

Journal: Hematological oncology
Published: January 02, 2024

Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes.

Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes.

Journal: Hematological oncology
Published: November 21, 2023

Upregulation of tumor suppressor PIAS3 by Honokiol promotes tumor cell apoptosis via selective inhibition of STAT3 tyrosine 705 phosphorylation.

Upregulation of tumor suppressor PIAS3 by Honokiol promotes tumor cell apoptosis via selective inhibition of STAT3 tyrosine 705 phosphorylation.

Journal: Journal of natural medicines
Published: July 04, 2023

Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.

Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.

Journal: International journal of cancer
Published: November 09, 2022

APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.

APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.

Journal: Leukemia
Published: October 24, 2021

A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma.

A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma.

Journal: Hematological oncology
Published: July 02, 2021
Showing 1-12 of 15

Last Updated: 09/26/2026